AVC-001 is under clinical development by AvenCell Europe and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVC-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVC-001 (GEM-3PSCA) is under development for the treatment of solid tumors like urogenital tract cancers including renal cell cancer, transitional cell cancer, castrate-resistant prostate cancer, pancreatic cancer and metastatic non-small cell lung, bladder cancer. The therapeutic candidate is administered through intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody being developed based on affinity-tailored adaptors for T-cells (ATAC) platform technology. It acts by targeting PSCA expressing cancer cells and CD3.
It was also under development for the treatment of breast cancer.
AvenCell Europe overview
AvenCell Europe formerly GEMoaB Monoclonals, is a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercialization of immunotherapies, which helps in treating the cancer patients. AvenCell Europe is headquartered in Dresden, Germany.
For a complete picture of AVC-001’s drug-specific PTSR and LoA scores, buy the report here.